Biotechs targeting cancer, immunology likely to draw buyout bids

07/13/2011 | Reuters

Biotech companies that specialize in drugs for cancer, immune system diseases and brain conditions are likely to become attractive acquisition targets for Big Pharma, said investment bankers and other industry experts. Among such firms are Seattle Genetics, which has a drug candidate for two rare types of blood cancer, and Biogen Idec, which has multiple sclerosis drugs on the market.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD